Second NICE draft still negative on Tyverb
This article was originally published in Scrip
GlaxoSmithKlineproposed an access scheme that would allow patients in the national health service in England and Wales with advanced or metastatic breast cancer to be treated with free Tyverb (lapatinib) for 12 weeks, but the plan has failed to persuade the National Institute for health and Clinical Excellence(NICE) that the product is cost-effective.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.